Stifel bumps Nvidia stock target, sees attractive valuation
Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics , Inc. (NASDAQ:TRDA), recently sold 1,784 shares of the company’s common stock. The transaction, which took place on March 17, 2025, was executed at a price of $10.67 per share, amounting to a total value of $19,035. The sale comes as TRDA shares trade near their 52-week low of $10.22, having declined approximately 40% year-to-date. According to InvestingPro data, analysts maintain price targets between $20-30, suggesting potential upside from current levels.
Following this transaction, Wentworth retains ownership of 109,536 shares in the company. InvestingPro analysis shows the company maintains a strong financial health score, with more cash than debt on its balance sheet and robust liquidity ratios. The sale was conducted under a Rule 10b5-1 trading plan, which had been adopted on March 15, 2024.
In other recent news, Entrada Therapeutics reported fourth-quarter earnings with a top line of $37.4 million and earnings per share of $0.03, surpassing both Oppenheimer’s projections and consensus estimates. Oppenheimer has maintained an Outperform rating with a $30 price target, reflecting confidence in the company’s progress. H.C. Wainwright also reiterated a Buy rating with a $20 price target, highlighting the FDA’s removal of the clinical hold on Entrada’s investigational drug ENTR-601-44 for Duchenne muscular dystrophy (DMD). The FDA’s decision allows the commencement of the ELEVATE-44-102 study, a Phase 1b clinical trial designed to evaluate the drug’s safety and efficacy.
Entrada Therapeutics has received authorization from the UK’s Medicines and Healthcare Products Regulatory Agency to initiate the ELEVATE-44-201 study, a Phase 1/2 trial of ENTR-601-44. This study will assess safety, tolerability, and efficacy in patients with a specific mutation in the DMD gene. The company’s proprietary Endosomal Escape Vehicle (EEV™) technology aims to restore dystrophin protein production, addressing the root cause of DMD. Additionally, the company has announced plans for global regulatory applications for other investigational drugs in its pipeline, including ENTR-601-50 and ENTR-601-51.
The ELEVATE-44 clinical program is a global effort to evaluate the treatment in a broad patient population, encompassing both early and advanced stages of DMD. Analysts from H.C. Wainwright have expressed optimism about Entrada’s regulatory progress, suggesting it could streamline future FDA approvals. Entrada’s CEO, Dipal Doshi, has expressed optimism about the potential of ENTR-601-44 to serve a significant portion of the adult DMD population. The company’s broader pipeline includes RNA-, antibody-, and enzyme-based programs targeting various diseases, further expanding its potential impact in the biopharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.